Navigation Links
Targeted drug may prolong survival of patients with cervical cancer
Date:3/9/2014

A new clinical study has found that erlotinib, a targeted antitumor agent, has promising potential to improve treatment for cervical cancer. Published early online in CANCER, a peer-reviewed journal of the American Cancer Society, the results indicate that larger trials are warranted to determine whether the drug should become part of standard therapy for women with the disease.

Nearly half a million new cases of cervical cancer are reported worldwide each year, making it the third most common cancer among females. Despite the widespread use of screening programs and the recent advent of vaccines against human papilloma virus, cervical cancer continues to be a significant public health problem.

Cisplatin-based chemoradiation is the standard therapy for locally advanced cervical cancer. Unfortunately, treatment responses are unpredictable and often disappointingly brief. A potentially promising new treatment strategy involves targeting the epithelial growth factor receptor (EGFR), which is frequently overexpressed in cervical cancer. Inhibiting this receptor is known to have antitumor effects against a variety of cancers.

Anglica Nogueira-Rodrigues, MD, PhD, of the Brazilian National Cancer Insitute, and her colleagues designed a phase 2 clinical trial to test the potential of the EFGR inhibitor erlotinib combined with chemoradiation therapy in 36 women with cervical cancer. Median duration of therapy was 77 days and median follow-up time was 59.3 months.

The therapy was well tolerated overall, and 34 patients (94.4 percent) achieved a complete response (meaning the disappearance of all cancerous lesions). After two years, 91.7 percent of women were alive, and 80.6 percent experienced no progression of their disease. After three years, 80 percent of women were alive, and 73.8 percent experienced no disease progression.

"While cervical cancer is a neglected disease and very few clinical trials have been reported
'/>"/>

Contact: Evelyn Martinez
sciencenewsroom@wiley.com
201-748-6358
Wiley
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Targeted therapeutics for colon cancer to be presented at AACR meeting
2. First targeted nanomedicine to enter human clinical studies
3. Highly targeted irradiation as good as whole breast radiotherapy in early stage cancer
4. Dana-Farber: Study reports first success of targeted therapy in type of non-small cell lung cancer
5. Inflammatory pathway spurs cancer stem cells to resist HER2-targeted breast cancer treatment
6. Killer infections targeted by hospital study
7. Lower risk of serious side-effects in trials of new targeted drugs
8. Treating drug resistant cancer through targeted inhibition of sphingosine kinase
9. Pitt: Targeted oxidation-blocker prevents secondary damage after traumatic brain injury
10. Deadly witch hunts targeted by grassroots womens groups
11. Large lung cancer study shows potential for more targeted therapies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2014)... 01, 2014 First Warning Systems, a ... cellular changes throughout the body, announced the company is ... address the company’s breadth of upcoming product releases. The ... screening technology. , “Our initial focus will be an ... detects abnormal circadian cellular changes over time,” said Rob ...
(Date:10/1/2014)... Farmington Company today announced it has ... visual identity helping brokers, consultants and companies to ... create greater benefit communication synergies. They unveiled a ... customers to better leverage Farmington Company’s industry-tested experience ... the rebrand is the refreshed tagline: For the ...
(Date:10/1/2014)... Hills, California (PRWEB) October 01, 2014 ... expert, Dr. Kathleen Mojas is celebrating 20 years of ... has assisted hundreds of people to achieve greater joy ... an important list of warning signs and suggestions for ... , Dr. Mojas explains: “Believe it or not, ...
(Date:10/1/2014)... Diet Doc understands that many of their ... and their dieting attempts could be easily sabotaged by the ... diet treatments into their programs as a way to ... and effective weight loss results, it also allows patients to ... maintain their weight for the future. , Earlier versions of ...
(Date:10/1/2014)... 2014 Scientists at the University of ... target immune system proteins has the power to knock ... details of the new study on their website. ... Researchers in the UWA School of Pathology and Laboratory ... mice with mesothelioma with promising results. , “A ...
Breaking Medicine News(10 mins):Health News:First Warning Systems Changes Name to Cyrcadia Health to Better Reflect Core Competency and Goals of Company 2Health News:First Warning Systems Changes Name to Cyrcadia Health to Better Reflect Core Competency and Goals of Company 3Health News:First Warning Systems Changes Name to Cyrcadia Health to Better Reflect Core Competency and Goals of Company 4Health News:Farmington Company Launches Rebrand and New Positioning 2Health News:Prominent Beverly Hills Psychologist Dr. Kathleen Mojas Celebrating 20 Years in Private Practice Identifies Common Warning Signs That You May Be In a Toxic Relationship. 2Health News:Prominent Beverly Hills Psychologist Dr. Kathleen Mojas Celebrating 20 Years in Private Practice Identifies Common Warning Signs That You May Be In a Toxic Relationship. 3Health News:Diet Doc Announces Their New Version of the Hormone Diet Plan to Target, Attack and Burn Fat Without Dangerous Side Effects 2Health News:Diet Doc Announces Their New Version of the Hormone Diet Plan to Target, Attack and Burn Fat Without Dangerous Side Effects 3Health News:Diet Doc Announces Their New Version of the Hormone Diet Plan to Target, Attack and Burn Fat Without Dangerous Side Effects 4Health News:New Mesothelioma Study Says Mice Cured by Immuntherapy “Cocktail”, Reports Surviving Mesothelioma 2
... It has been reported that bacteria lurking in ... called endotoxins that may trigger asthma and asthma-related ... association has been established between endotoxin levels and ... medication use, and wheezing. These relationships were strongest ...
... says that a combination of newer drugs for ... ,Hypertension is the most important preventable cause of ... of anti-hypertensive drugs for prevention of cardiovascular mortality ... trial using standard diuretic or Beta-blocker therapy, or ...
... report published by the Department of Veterans Affairs (VA) ... levels and provided a guideline to do so.// ... heart and blood vessels, but they may also increase ... Alzheimer’s disease. ,During September, celebrating the National Cholesterol ...
... acid as found to reduce the rate of birth defects. ... found that more than one third of birth defects are ... Spina bifida and anencephaly, known as neural-tube defects, arise when ... close during the first weeks of pregnancy. The defect causes ...
... the current edition of Pediatrics that use of alcohol based ... gastro-intestinal infections.// ,In a study of 292 Greater Boston ... those that used the gel had a 59 percent reduction ... day care centers, and all had a least one child ...
... from the Stanford University School of Medicine have reported the ... result of the study has found that //high doses of ... growth of cancer in patients with prostate cancer. The study ... the growth of prostate cancer by 70 percent. ...
Cached Medicine News:Health News:Is your house safe enough to protect against asthma attacks? 2Health News:High Cholesterol Can Be Controlled By Screening And Prevention 2Health News:Folic acid enriched grain reduces birth defects 2Health News:Less Stomach Infections If Hand Sanitizer Gel Is Used 2
(Date:10/2/2014)... 1, 2014 The global high content screening ... the ,Threat of Obsolescence, wherein technologies as well as ... and biotechnology companies as well as academic and government ... as a powerful research tool in drug discovery. The ... in the high content screening market. In high content ...
(Date:10/1/2014)... Oct. 1, 2014  Dyadic International, Inc. ("Dyadic") ... and proprietary technology used to develop and produce ... chemicals, biopharmaceuticals, and industrial enzymes industries, today announced ... Abengoa Bioenergy for commercial scale production of Abengoa,s ... ethanol, developed under Abengoa,s license agreement with Dyadic. ...
(Date:10/1/2014)... 1, 2014 Trovagene, Inc., (NASDAQ:  TROV) ... that Eli Diamond , MD, Assistant Attending ... presented clinical data from an ongoing study demonstrating ... for the determination of oncogene mutational status in ... results were presented to both treating physicians and ...
Breaking Medicine Technology:High Content Screening Market by Instruments (Cell Imaging and Analysis System), by Applications (Primary and Secondary Screening, Target Identification and Validation, Toxicity Studies, Compound Profiling), Software & Services - Global Forecasts to 2High Content Screening Market by Instruments (Cell Imaging and Analysis System), by Applications (Primary and Secondary Screening, Target Identification and Validation, Toxicity Studies, Compound Profiling), Software & Services - Global Forecasts to 3Dyadic International Reports Licensing Payment For Commercial-Scale Production Of C1-Based Cellulase Enzymes 2Dyadic International Reports Licensing Payment For Commercial-Scale Production Of C1-Based Cellulase Enzymes 3Clinical Performance of Trovagene's Precision Cancer Monitoring Platform Presented at Second Annual International ECD Medical Symposium 2Clinical Performance of Trovagene's Precision Cancer Monitoring Platform Presented at Second Annual International ECD Medical Symposium 3Clinical Performance of Trovagene's Precision Cancer Monitoring Platform Presented at Second Annual International ECD Medical Symposium 4
... The Leukemia & Lymphoma,Society has awarded a $550,000 grant ... Cancer Center at the University of Rochester Medical,Center. Millennium ... the first two years of the five-year program., ... support,Dr. Friedberg,s work on a new targeted treatment for ...
... Medivation, Inc.,(Nasdaq: MDVN ) today announced that ... on Monday, July 7, to discuss top-line results ... of,dimebon(TM) in Huntington,s disease., Teleconference/Webcast Details, ... July 7, at 5:00 p.m. Eastern,time by telephone, ...
Cached Medicine Technology:University of Rochester Researcher Named Millennium Pharmaceuticals Career Development Scholar of The Leukemia & Lymphoma Society 2Medivation to Host Conference Call at 5 p.m. EDT Monday to Discuss Top-Line Phase 2 Study Results in Huntington's Disease 2
... PACHETT 3 uses the exact enhanced corneal ... DGH pachymeters used exclusively by the OHTS ... into the software. The new backlit LCD ... average, standard deviation and IOP correction calculation ...
The Medmont C100 Colour Vision Tester is an electronic colour vision screening device which is used to rapidly detect red/green colour vision deficiencies. Its high sensitivity provides a positive in...
... E300 Corneal Topographer has applications ... clinical procedures including Radial Keratotomy, ... Contact Lens Fitting. Based on ... the E300 analyses an accurate ...
... first Open Bore MR ,Siemens has combined, for ... bore, a very short 125 cm magnet and ... very revolutionary: Open Bore MR. And MAGNETOM Espree, ... A unique Siemens technology, which means faster, more ...
Medicine Products: